Actively Recruiting
Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
Led by Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. · Updated on 2025-03-19
20
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
CONDITIONS
Official Title
Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female sex
- Age 18 - 75 years old
- Diagnosed with Stage II or III Triple Negative Breast Cancer and candidates for neoadjuvant chemotherapy with pembrolizumab after multidisciplinary group discussion
You will not qualify if you...
- Unable to understand or consent to the study
- Not completing at least 2 cycles of planned neoadjuvant pembrolizumab or at least 50% of planned neoadjuvant chemotherapy cycles
- Taking daily prednisolone or equivalent steroid at doses of 10 mg or more
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centro Hospitalar Vila Nova de Gaia/Espinho
Vila Nova de Gaia, Região, Portugal, 4434-502
Actively Recruiting
Research Team
A
Alexandra P. Guedes, Medical Oncologist M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here